BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24359127)

  • 1. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.
    Sinha R; Lecamwasam K; Purshouse K; Reed J; Middleton MR; Fearfield L
    Br J Dermatol; 2014 Apr; 170(4):997-9. PubMed ID: 24359127
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
    Jeudy G; Dalac-Rat S; Bonniaud B; Hervieu A; Petrella T; Collet E; Vabres P
    Br J Dermatol; 2015; 172(5):1454-5. PubMed ID: 25384395
    [No Abstract]   [Full Text] [Related]  

  • 3. [Vemurafenib-induced toxic epidermal necrolysis].
    Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P
    Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxic epidermal necrolysis induced by vemurafenib.
    Lapresta A; Dotor A; González-Herrada C
    Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
    [No Abstract]   [Full Text] [Related]  

  • 5. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
    Bellón T; Lerma V; González-Valle O; González Herrada C; de Abajo FJ
    Br J Dermatol; 2016 Mar; 174(3):621-4. PubMed ID: 26412570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib-induced bilateral facial palsy.
    Shailesh FN; Singh M; Tiwari U; Hutchins LF
    J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.
    Mangold AR; Bryce A; Sekulic A
    J Am Acad Dermatol; 2014 Nov; 71(5):e205-6. PubMed ID: 25437992
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
    Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
    J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
    [No Abstract]   [Full Text] [Related]  

  • 9. Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure.
    Arenbergerova M; Mrazova I; Horazdovsky J; Sticova E; Fialova A; Arenberger P
    J Eur Acad Dermatol Venereol; 2017 May; 31(5):e253-e254. PubMed ID: 27739125
    [No Abstract]   [Full Text] [Related]  

  • 10. [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].
    Demirtas S; El Aridi L; Acquitter M; Fleuret C; Plantin P
    Ann Dermatol Venereol; 2017 Jan; 144(1):65-66. PubMed ID: 28011090
    [No Abstract]   [Full Text] [Related]  

  • 11. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
    Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
    J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
    [No Abstract]   [Full Text] [Related]  

  • 12. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma.
    Degen A; Völker B; Kapp A; Gutzmer R
    Eur J Dermatol; 2013; 23(1):118. PubMed ID: 23419281
    [No Abstract]   [Full Text] [Related]  

  • 14. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

  • 17. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption.
    Gupta M; Huang V; Linette G; Cornelius L
    Arch Dermatol; 2012 Aug; 148(8):966-8. PubMed ID: 22911209
    [No Abstract]   [Full Text] [Related]  

  • 19. Vemurafenib. Value unclear in metastatic melanoma.
    Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of occipital neuralgia in a vemurafenib-treated melanoma patient.
    Hoashi T; Matsumoto N; Serizawa N; Kataoka K; Nako T; Shirakawa N; Matano Y; Funasaka Y; Saeki H
    Int J Dermatol; 2017 Jan; 56(1):e10-e11. PubMed ID: 27653311
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.